{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-26-000043","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2026-06-11T12:02:57+00:00","discovered_at":"2026-06-11T12:05:00.345202+00:00","generated_at":"2026-06-11T12:05:15.552866+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caribou reports vispa-cel 82% ORR, 17.1mo mPFS in 2L LBCL; CB-011 83% CR rate in MM","bullets":["Vispa-cel in 27 optimized 2L LBCL patients: 82% ORR, 67% CR, 17.1 months median PFS.","Vispa-cel safety: no GvHD, no grade 3+ ICANS; one grade 3+ CRS; one related death (IEC-HS).","FDA aligned on ANTLER-3 phase 3 design for vispa-cel; ~250 CD19-naïve 2L LBCL patients, primary endpoint PFS.","CB-011 in 12 BCMA-naïve r/r MM patients at RDE: 92% ORR, 83% ≥CR, 91% MRD negativity, 50% in ≥CR at 15 months.","CB-011 case study: patient after 8 prior lines (incl. autologous CAR-T) achieved CR; dose expansion data expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-26-000043","json":"https://secwatch.observer/filing/0001619856-26-000043.json","markdown":"https://secwatch.observer/filing/0001619856-26-000043.md","text":"https://secwatch.observer/filing/0001619856-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985626000043/0001619856-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985626000043/crbu-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:05:15.552866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}